SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES

Retina ◽  
2016 ◽  
Vol 36 (2) ◽  
pp. 285-298 ◽  
Author(s):  
Melissa M. Brown ◽  
Gary C. Brown ◽  
Heidi B. Lieske ◽  
Irwin Tran ◽  
Adam Turpcu ◽  
...  
Keyword(s):  
United States ◽  
Macular Degeneration ◽  
The United States ◽  
Age Related Macular Degeneration ◽  
Societal Costs ◽  
Age Related

scholarly journals SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States

2020 ◽  
Vol 4 (2) ◽  
pp. 122-133 ◽  
Author(s):  
Arshad M. Khanani ◽  
Adrian Skelly ◽  
Vladimir Bezlyak ◽  
Ray Griner ◽  
Laura Rodriguez Torres ◽  
...  
Keyword(s):  
United States ◽  
Macular Degeneration ◽  
Real World ◽  
The United States ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Real World Evidence

Bevacizumab cured age-related macular degeneration (AMD) via down-regulate TLR2 pathway

2014 ◽  
Vol 9 (5) ◽  
pp. 469-475 ◽  
Author(s):  
Zhi Wang ◽  
Bao Qiao ◽  
Guo Li ◽  
Shi Li ◽  
Li Wang ◽  
...  
Keyword(s):  
United States ◽  
Macular Degeneration ◽  
The United States ◽  
Age Related Macular Degeneration ◽  
Toll Like Receptor ◽  
Neovascular Amd ◽  
Common Cause ◽  
Rpe Cells ◽  
Age Related ◽  
Toll Like Receptor 2

AbstractAMD is the main cause of visual impairment in people over 50 years of age and the most common cause of blindness. In recent years, the use of bevacizumab to treat neovascular AMD has become a preferred treatment in the United States. However, whether bevacozumab is available for RPE or AMD patients is unknown. We firstly indicate that Pam3CSK4 (P3C) activates TLR2 pathway during ARPE-19 apoptosis as determined by western blotting. And then, the expression of MyD88, NF-κB, p-IKK in primary RPE cells from AMD patients is significantly down-regulated after treatment with 50 µg L−1 Bevacizumab. Therefore, our data shows that MyD88 is involved in the TLR2 pathway in ARPE-19 cell apoptosis resulting from Pam3CSK4 (P3C). And more importantly, our findings suggested that Bevacizumab cured age-related macular degeneration (AMD) via down-regulate Toll—like receptor 2 (TLR2) pathway in RPE from AMD patients.

Sign in / Sign up

Export Citation Format

Share Document